argenx SE (ARGNF)

OTCMKTS · Delayed Price · Currency is USD
630.00
+14.23 (2.31%)
At close: Dec 23, 2024
69.81%
Market Cap 37.37B
Revenue (ttm) 1.91B
Net Income (ttm) -40.29M
Shares Out n/a
EPS (ttm) -0.68
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 10
Open 630.00
Previous Close 615.77
Day's Range 630.00 - 630.00
52-Week Range 341.00 - 540.00
Beta 0.31
Analysts n/a
Price Target n/a
Earnings Date Feb 27, 2025

About argenx SE

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 1,148
Stock Exchange OTCMKTS
Ticker Symbol ARGNF
Full Company Profile

Financial Performance

In 2023, argenx SE's revenue was $1.27 billion, an increase of 187.66% compared to the previous year's $441.01 million. Losses were -$295.05 million, -58.42% less than in 2022.

Financial Statements

News

Biohaven Advances in Immunotherapy: Significant IgG Reduction Achieved with BHV-1300, Gains Analyst Approval

On Monday, Biohaven Ltd. (NYSE: BHVN) revealed clinical and regulatory milestones across its proprietary Molecular Degrader of Extracellular Proteins (MoDE) platform and its glutamate modulation and ...

6 days ago - Benzinga

argenx to Present at Upcoming Investor Conferences

November 26, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today...

4 weeks ago - GlobeNewsWire

argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies

Phase 2 data establish proof-of-concept of efgartigimod SC in myositis Enrollment to continue in Phase 3 across all three subtypes (IMNM, ASyS, DM) under evaluation in ALKIVIA Potential for efgartigim...

4 weeks ago - GlobeNewsWire

Steritas Announces Collaboration with argenx to Advance Evidence for Novel Steroid-sparing Therapeutics

BOSTON--(BUSINESS WIRE)--Steritas LLC., a company dedicated to enhancing care for steroid-treated patients, today announced a licensing agreement with argenx, a global immunology company, for use of i...

4 weeks ago - Business Wire

(ARGX) - Analyzing argenx's Short Interest

argenx's (NYSE: ARGX) short percent of float has fallen 4.38% since its last report. The company recently reported that it has 1.70 million shares sold short , which is 2.84% of all regular shares th...

5 weeks ago - Benzinga

This Bristol-Myers Squibb Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page . Wolfe Res...

5 weeks ago - Benzinga

Argenx upgraded at Wolfe on myasthenia gravis dominance

Argenx (ARGX) stock upgraded at Wolfe Research citing dominance in myasthenia gravis market and profitability outlook. Read more here.

5 weeks ago - Seeking Alpha

argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China

First and only NMPA-approved treatment for patients with CIDP in China  Second VYVGART Hytrulo indication approved in China  November 11, 2024 – 7:30am ET  Amsterdam, the Netherlands— argenx SE (Euron...

6 weeks ago - GlobeNewsWire

Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & Nasdaq: ARGX) today announced that China's National Medical Products Administration (NMP...

6 weeks ago - Business Wire

Peering Into argenx's Recent Short Interest

argenx's (NYSE: ARGX) short percent of float has fallen 11.08% since its last report. The company recently reported that it has 1.78 million shares sold short , which is 2.97% of all regular shares t...

6 weeks ago - Benzinga

argenx to Participate at Upcoming Investor Conferences

November 5, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today ...

7 weeks ago - GlobeNewsWire

This Atlassian Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page . Mizuho an...

7 weeks ago - Benzinga

argenx downgraded at Baird as shares get pricey

argenx stock downgraded to neutral at Baird due to high valuation despite strong Q3 performance. Read more here.

7 weeks ago - Seeking Alpha

argenx SE (ARGX) Q3 2024 Earnings Call Transcript

argenx SE (NASDAQ:ARGX) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ETCompany ParticipantsBeth DelGiacco – Vice President, Corporate...

7 weeks ago - Seeking Alpha

Argenx SE reports Q3 results

7 weeks ago - Seeking Alpha

argenx Reports Third Quarter 2024 Financial Results and Provides Business Update

$573 million in third quarter global net product sales CIDP global expansion on track, with decisions on approval under review in Japan, Europe, China, and Canada Management to host conference call to...

7 weeks ago - GlobeNewsWire

Argenx SE Q3 2024 Earnings Preview

7 weeks ago - Seeking Alpha

argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024

October 24, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today ...

2 months ago - GlobeNewsWire

argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions

Long-term and real-world data of VYVGART® (efgartigimod alfa-fcab) and VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrate speed of onset, depth of response, and durability of resp...

2 months ago - GlobeNewsWire

Biotech Leader Argenx In Buy Zone, Poised To Hit New Highs

Argenx stock is in a buy zone on the stock market today after a recent breakout and the biotech leader is poised to hit new highs.

2 months ago - Investor's Business Daily

Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases

Argenx stock surged Wednesday after Amgen presented "underwhelming" results for a potential competitor to Vyvgart in an autoimmune disease.

3 months ago - Investor's Business Daily

argenx: Myositis Data Could Add Billions In Value

argenx leads in FcRn market with Vyvgart, poised for growth in autoimmune diseases and supports a bullish outlook. Read more on ARGX here.

3 months ago - Seeking Alpha

argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy

ADHERE was largest and most innovative clinical trial of CIDP patients to date VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrated reduction in disease progression, reduced risk o...

3 months ago - GlobeNewsWire